Veranex Acquires Medidee
Veranex, a global, tech-enabled service provider dedicated to the medical technology industry, has acquired MedTech consultancy Medidee, headquartered in Lausanne, Switzerland.
The acquisition will expand and strengthen Veranex’s regulatory affairs, clinical development and quality assurance services for medtech companies, including an improved ability to navigate EU-MDR/IVDR challenges thanks to Medidee’s experience in the European regulatory space.
“Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage,” said David Dockhorn, CEO of Veranex. “The combined organization offers offices and expertise across Europe, the U.S. and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.”
Medidee has 11 locations across Europe, India and Asia-Pacific. Veranex has 13 locations across the U.S., Europe and China. The combined companies will offer a full spectrum of integrated concept-to-commercialization services, including design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy and market access services.
Related Articles
-
The acquisition expands Veranex’s footprint for product design engineering services across the U.S., with combined company offices now in the Eastern, Central, and Western regions
-
The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.
-
Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.
-
The expansion of BlackHӓgen’s HFE team and other critical usability-focused design groups, such as the UX team, will support the company’s ability to deliver its expertise to a wider range of MedTech customers.
